Designing Solutions Discovering Biology Delivering Hope

ZielBio is a biotechnology company using groundbreaking technology that reveals actionable insights to develop new therapeutic modalities to meaningfully improve patients’ lives.
A man and woman walk forward together holding hands. They are smiling and looking into each other’s eyes.

Reimagining drug discovery

Using our proprietary drug discovery platform, ZielBio identifies druggable and specific targets that have the potential to radically change how we treat disease. Learn more about our targets.
A man and woman walk forward together holding hands. They are smiling and looking into each other’s eyes.

Innovative therapies for novel disease targets

With new targets come new possibilities to transform the future of medicine and patient care. We are advancing several therapeutics to expand treatment options for patients with cancer and other serious diseases. Learn more about our therapies.

Hope for patients in need

We have preliminary clinical data from a Ph 1 study with our anti-CSP monoclonal antibody, ZB131, demonstrating safety and tolerability in a cohort of patients with a variety of solid tumors. We are currently optimizing the use of ZB131 and developing several oncology therapeutics leveraging our knowledge of this target and this antibody.

News and resources

Latest news from ZielBio
June 02, 2023

ZielBio to Present Interim Findings from its Phase 1/2, First-in-Human Trial of ZB131 at 2023 ASCO Annual Meeting

READ MORE
April 17, 2023

ZielBio to Present New Research on the Utility of Cancer-Specific Plectin (CSP) and ZB131 in Antibody-Drug Conjugates at AACR Annual Meeting 2023

READ MORE
January 03, 2023

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics

READ MORE
December 23, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer

READ MORE